PaO2/FIO2-基于分层对ARDS的非输管受试者治疗失败进行歧视
Masaaki Sakuraya1,2, Kazuma Nagata3, Toshiki Yokoyama4
1Dr. Sakuraya is affiliated with Department of Emergency and Intensive Care Medicine, JA Hiroshima General Hospital, Hatsukaichi, Japan.
Respiratory care
|September 26, 2025
概括
PaO2/FiO2比率有助于预测ARDS的非输管患者的治疗失败. 持续正气道压力 (CPAP) 在预测结果方面可能比高流量鼻 (HFNC) 更有效.
科学领域:
- 关键护理医学 关键护理医学
- 呼吸系统医学 呼吸系统医学
- 肺部疾病 肺部疾病
背景情况:
- 急性呼吸困难综合征 (ARDS) 的新全球定义适用于接受高流量鼻管 (HFNC) 的非输管患者.
- 在ARDS中使用PaO2/FiO2比率对HFNC进行分层,需要验证.
- 对于预测ARDS结果的HFNC和连续正气道压力 (CPAP) 之间的氧化评估差异尚不清楚.
研究的目的:
- 调查HFNC和CPAP之间氧化评估的差异,以预测非输管ARDS患者的治疗失败.
- 评估PaO2/FiO2分层对HFNC患者的有效性.
- 为了比较PaO2/FiO2在HFNC和CPAP之间治疗失败的歧视性性能.
主要方法:
- 在日本的一项多中心随机对照试验的后期分析.
- 在CPAP上PaO2/FiO2<300的受试者被分配到HFNC或继续CPAP.
- 根据CPAP期间的PaO2/FiO2水平,分层分为轻度,中度和严重的低氧症.
- 治疗失败 (输管或住院死亡) 是主要结果.
- 接收器运行特征曲线下的面积 (AUROC) 评估了设备的区分性性能.
主要成果:
- 治疗失败率随着低氧化症的严重程度增加:轻度 (3.2%),中度 (25.0%) 和严重 (50.0%).
- 在30分钟后,HFNC患者的44.7%出现了氧化恶化,而CPAP患者的2.6% (P < .001).
- 与CPAP (0.82,P = .041) 相比,HFNC显示PaO2/FiO2的AUROC较低,预测治疗失败 (0.66) 与CPAP (0.82,P = .041) 相比.
结论:
- 基于PaO2/FiO2的分层可以帮助预测非输管ARDS患者的治疗失败.
- 由于呼吸辅助器械而导致氧化评估的变化需要进行彻底评估.
- 与HFNC相比,CPAP可能表现出治疗失败的优异预测性能.
相关概念视频
Acute Respiratory Failure-I
855
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
855
Acute Respiratory Failure-II
1.0K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
589
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
589
Acute Respiratory Failure-IV
513
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
513
Acute Respiratory Failure-V
462
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
462
Acute Respiratory Failure-III
788
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
788


